PharmaceuticalSedativeZ-drugHypnotic

Zaleplon

Also known as Sonata · Starnoc

Written by enwyReviewed 15 Jul 20261 sources0 comments

Zaleplon is a licensed pyrazolopyrimidine hypnotic (Sonata) with a very short half-life, used for sleep-onset insomnia. Its brief duration limits next-day sedation and even permits middle-of-the-night dosing. It still carries the Z-drug risks of dependence and complex sleep behaviours.

01 Overview

Zaleplon, marketed as Sonata, is a short-acting Z-drug indicated for difficulty falling asleep. Its very short half-life means it clears quickly, so it produces little next-morning impairment and can, in some circumstances, be taken during the night provided several hours remain before waking.

It acts at the GABA-A benzodiazepine site with alpha-1 preference. While its brevity reduces daytime carryover, it shares the class liabilities of dependence, rebound insomnia and complex sleep behaviours such as sleep-walking with amnesia.

02 Mechanism

Positive allosteric modulator at the GABA-A benzodiazepine site (pyrazolopyrimidine) with alpha-1 subunit preference; ultra-short duration of action.

03 Dosing

Tier	Dose	Route	Notes
Therapeutic (adult)	5–10 mg/day	Oral	At bedtime with at least 4 hours of sleep remaining; 5 mg in the elderly or hepatic impairment.

04 Effects

Effect	Magnitude	Evidence
Reduced sleep latencyFalls asleep faster, shown in controlled trials.		Clinical
Minimal next-day carryoverShort half-life limits residual morning sedation compared with other hypnotics.		Clinical
SedationBrief CNS depression to initiate sleep.		Clinical

05 Side effects

Effect	Severity	Frequency	Evidence
Dependence and rebound insomniaTolerance and dependence with continued use; rebound insomnia on stopping.	Moderate	Common with prolonged use	Clinical
Complex sleep behavioursSleep-walking and related behaviours with amnesia, part of the Z-drug class warning.	Severe	Rare	Observational
Additive respiratory depressionDangerous with opioids or alcohol.	Life-threatening	High risk in combination	Clinical

06 Legal status

United States

Schedule IV controlled substance

as of Jan 2026

United Kingdom

Prescription-only

as of Jan 2026

07 References

Zaleplon (Sonata) FDA prescribing informationUS FDA

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.